Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RC48”

78 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 78 results

Testing effectiveness (Phase 2)UnknownNCT05135715
What this trial is testing

RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Who this might be right for
Melanoma, Stage IIHER2-positiveAdvanced Melanoma
RemeGen Co., Ltd. 50
Not applicableLooking for participantsNCT05831878
What this trial is testing

RC48-ADC in HER2-low Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
RenJi Hospital 36
Testing effectiveness (Phase 2)Looking for participantsNCT05403242
What this trial is testing

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

Who this might be right for
Advanced Gastroesophageal Adenocarcinoma
Chinese PLA General Hospital 42
Testing effectiveness (Phase 2)UnknownNCT06178601
What this trial is testing

RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Urothelial Carcinoma
Shanxi Province Cancer Hospital 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05356351
What this trial is testing

An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer

Who this might be right for
Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07100184
What this trial is testing

RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients

Who this might be right for
HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT
Peking University First Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07172217
What this trial is testing

The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC

Who this might be right for
Recurrent Cervical Cancer
Qilu Hospital of Shandong University 33
Testing effectiveness (Phase 2)Looking for participantsNCT04879329
What this trial is testing

Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Who this might be right for
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer 372
Testing effectiveness (Phase 2)Looking for participantsNCT06540729
What this trial is testing

RC48 in Combination With AK104 and Bevacizumab in OCCC

Who this might be right for
Ovary Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 39
Testing effectiveness (Phase 2)Looking for participantsNCT07065435
What this trial is testing

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Who this might be right for
HER2 + Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 74
Testing effectiveness (Phase 2)Looking for participantsNCT06063018
What this trial is testing

RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

Who this might be right for
Cervical Cancer Recurrent
Peking Union Medical College Hospital 30
Testing effectiveness (Phase 2)Study completedNCT03556345
What this trial is testing

RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2

Who this might be right for
Gastric CancerHER2 Overexpressing Gastric Carcinoma
RemeGen Co., Ltd. 127
Testing effectiveness (Phase 2)UnknownNCT04965519
What this trial is testing

RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies

Who this might be right for
Gynecological Malignancy
RemeGen Co., Ltd. 120
Not applicableUnknownNCT05540483
What this trial is testing

RC-48 Combined With GLS-010 in HER2-overexpressed Patients With Previously Treated Unresectable Biliary Tract Cancer

Who this might be right for
Biliary Carcinoma
The First Affiliated Hospital with Nanjing Medical University 31
Testing effectiveness (Phase 2)Looking for participantsNCT07311577
What this trial is testing

Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study

Who this might be right for
Ovarian Cancer MetastaticOvarian Cancer Metastatic Recurrent
Jiangsu Cancer Institute & Hospital 43
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07201675
What this trial is testing

Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment

Who this might be right for
Muscle Invasive Bladder Cancer (MIBC)
Qilu Hospital of Shandong University 59
Large-scale testing (Phase 3)Looking for participantsNCT05904964
What this trial is testing

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

Who this might be right for
HR Positive/HER2 Low Expression Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 288
Early research (Phase 1)Study completedNCT02881138
What this trial is testing

RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors

Who this might be right for
Solid Tumors
RemeGen Co., Ltd. 24
Testing effectiveness (Phase 2)Looking for participantsNCT06341400
What this trial is testing

RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients

Who this might be right for
Bladder CancerMuscle-Invasive Bladder Carcinoma
Zhujiang Hospital 55
Testing effectiveness (Phase 2)Study completedNCT03809013
What this trial is testing

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

Who this might be right for
Urothelial Carcinoma
RemeGen Co., Ltd. 64
Load More Results